

# VU Research Portal

## Metabolic imaging in gluco-lipotoxic heart and liver disease in type 2 diabetes

Rijzewijk, L.J.

2011

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Rijzewijk, L. J. (2011). *Metabolic imaging in gluco-lipotoxic heart and liver disease in type 2 diabetes*.

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

## **Contents**

<b>Introduction</b>	<b>9</b>
<b>PART 1 – Diabetes and The Heart</b>	
<b>Chapter 1</b>	
Diabetic Gluco-Lipotoxic Cardiomyopathy: Amendable by Metabolic Manipulation? <i>European Endocrinology. 2008;4:54-61.</i>	<b>17</b>
<b>Chapter 2</b>	
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. <i>J Am Coll Cardiol, 2008;52:1793-9.</i>	<b>39</b>
<b>Chapter 3</b>	
Altered Myocardial Substrate Metabolism and Decreased Diastolic Function in Non-Ischemic Human Diabetic Cardiomyopathy: Studies with Cardiac PET and MRI. <i>J Am Coll Cardiol. 2009;54:1524-32</i>	<b>53</b>
<b>Chapter 4</b>	
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. <i>Circulation. 2009;119:2069-2077</i>	<b>69</b>
<b>Chapter 5</b>	
Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. <i>J Am Coll Cardiol. 2010;56:225-33.</i>	<b>87</b>
<b>PART 2 – Diabetes and The Liver</b>	
<b>Chapter 6</b>	
Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism. <i>Diabetes. 2010;59:2747-54.</i>	<b>105</b>
<b>Chapter 7</b>	
Differential effects of pioglitazone and metformin on hepatic triglyceride content, substrate metabolism and perfusion in type 2 diabetic patients. <i>Submitted</i>	<b>121</b>

## **PART 3 - Methodology**

### **Chapter 8**

Kinetic models for analyzing myocardial [11C]palmitate data. **135**  
*Eur J Nucl Med Mol Imaging. 2009;36(6):966-78.*

### **Chapter 9**

Stroke volume measurements with first-pass dynamic positron emission tomography: **157**  
Comparison with cardiovascular magnetic resonance.  
*J Nucl Card. 2008;15:218-24.*

### **Chapter 10**

General discussion (adapted from the review: Diabetic glucolipotoxic cardiomyopathy: **169**  
does it exist in humans?)  
*Submitted*

**Summary** **203**

**Samenvatting** **209**

**Publications** **217**

**Dankwoord** **225**

**Curriculum Vitae** **231**